Crescent Biopharma, Inc. (CBIO) Dividend History
Income profile from 2011 to 2025 with payout safety and yield-on-cost trend
CBIO Dividend Income Check
Safety
Payout ratio data not available yet.
Consistency
0 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
CBIO Dividend Scorecard
Yield & Income
Payout Safety
Growth
Total Returns
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). CBIO's recent 5Y regime has been stronger than its full 10Y period, so 5Y can appear higher than 10Y.
CBIO Dividend History
No dividend payment history available
Get CBIO's next ex-dividend date and payout in your inbox
Monthly dividend calendar — upcoming ex-dates for stocks you follow.
Dividend Analysis
Payout Safety
Crescent Biopharma, Inc. has limited earnings payout data (Unknown).
Piotroski F-Score: 7/9 — strong financial health.
Growth Track Record
CBIO does not have a current streak of consecutive dividend increases.
Total Shareholder Returns
Beyond cash dividends, CBIO returns capital through share repurchases. The combined picture: 0.0% buyback yield, 0.0% total shareholder yield.
Income Trend & Total Return
The 5-year total return is -93.3%.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $233 today.
CBIO Annual Dividend History (2011–2025)
15 years of dividend data
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | — | 0 | $-12.81 | — | — | — |
| 2024 | $0.00 | — | 0 | $-1.40 | — | — | — |
| 2023 | $0.00 | — | 0 | $-0.58 | — | — | — |
| 2022 | $0.00 | — | 0 | $-0.89 | — | — | — |
| 2021 | $0.00 | — | 0 | $-1.23 | — | — | — |
| 2020 | $0.00 | — | 0 | $-1.12 | — | — | — |
| 2019 | $0.00 | — | 0 | $-1.34 | — | — | — |
| 2018 | $0.00 | — | 0 | $-1.18 | — | — | — |
| 2017 | $0.00 | — | 0 | $-1.13 | — | — | — |
| 2016 | $0.00 | — | 0 | $-1.50 | — | — | — |
What if you invested $1,000 in CBIO back in 2011?
Total return with dividends reinvested · 15+ years of data
Calculate ReturnsHow much would $100/month in CBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCBIO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowCBIO — Frequently Asked Questions
Quick answers to the most common questions about buying CBIO stock.
How much dividend does CBIO pay per share?
Crescent Biopharma, Inc. (CBIO) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made quarterly.
When is CBIO's next ex-dividend date?
CBIO's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. CBIO typically pays dividends quarterly.
Is CBIO's dividend safe?
CBIO's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The dividend history does not yet show a prolonged growth streak.
How many years has CBIO increased its dividend?
CBIO has not maintained a consecutive growth streak recently. The 5-year dividend CAGR is N/A.
How often does CBIO pay dividends?
Crescent Biopharma, Inc. pays dividends quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 14+ years from 2011 to 2025.
How much would $10,000 invested in CBIO grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in CBIO five years ago would be worth approximately $667 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is CBIO's yield on cost for long-term holders?
CBIO's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.